Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find PharmaFlow Article for Cyclophosphamide

    Client Email Product

    Cyclophosphamide

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    39
    US DMFs Filed

    US DMFs Filed

    21
    CEP/COS Certifications

    CEP/COS Certifications

    5
    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    6
    Other Suppliers

    Other Suppliers

    22
    API REF. PRICE (USD / KG)
    1,314

    API Market Place

    14
    INTERMEDIATES
    3
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    75
    Europe

    Europe

    15
    Canada

    Canada

    6
    Australia

    Australia

    11
    South Africa

    South Africa

    6
    Uploaded Dossiers

    Uploaded Dossiers

    22
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    37.00

    Annual Reports

    0

    FDF Market Place

    18
    EXCIPIENTS
    136
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    12

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    68
    REF STANDARD

    EDQM

    1

    USP

    5

    JP

    0

    Other Listed Suppliers

    5
    SERVICES

    0

    left grey arrow
    right gray arrow
    • INJECTABLE;INJECTION - 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • INJECTABLE;INJECTION - 1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • INJECTABLE;INJECTION - 200MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • INJECTABLE;INJECTION - 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • INJECTABLE;INJECTION - 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • CAPSULE;ORAL - 25MG
    • CAPSULE;ORAL - 50MG
    BlogBlog
    Full View ScreenFull Screen View
    Zhejiang Hisun’s FDA import alert; a new chapter in the fight against data integrity

    Zhejiang Hisun’s FDA import alert; a new chapter in the fight against data integrity

    A few months ago, PharmaCompass covered the Health Canada request to quarantine drugs linked to leading Chinese drug maker, Zhejiang Hisun Pharma (Hisun) due to data integrity concerns.The “interim precautionary measure” was taken “in light of recent findings from a trusted regulatory partner that raised concerns about the reliability of the laboratory data generated at this site”.Last week, the trusted regulatory partner – i.e. the United States Food and Drug Administration (FDA) – announced it had placed Zhejiang Hisun Pharma on its import alert list. Regulators unite against data integrity violations International regulatory agencies are collaborating with each other at an unprecedented pace. Health Canada’s decision to quarantine drugs from Hisun almost three months before FDA’s official action indicates an extremely low level of tolerance for companies that fail to maintain data integrity. Health Canada has also taken similar action against companies who have recently failed European inspections (e.g. India’s Polydrug Laboratories and China’s Jinan Jinda Pharmaceutical Chemistry). Polydrug Laboratories was also included in the most recent FDA Import Alert list indicating a growing impatience in international regulatory agencies against non-compliant firms. Last week, Brazilian Health Surveillance Agency (ANVISA) announced suspending import of all APIs from India’s Parabolic Drugs. ANVISA’s resolution was driven by Parabolic’s failure of a European Good Manufacturing Practices (GMP) inspection in July this year   Hisun’s importance in the pharmaceutical supply chainThe FDA decision to ban almost all products coming from the Hisun facilities into the United States is going to create significant disruption in the pharmaceutical supply chain, given the colossal scale of Hisun Pharma’s operations.Zhejiang Hisun Pharma qualifies as one of the most prominent active pharmaceutical ingredients (API) manufacturers in the business, with more than 93 Drug Master Files submitted with the FDA, four approved finished products listed in the FDA Orange Book and 35 Certificates of Suitability issued by the European Directorate of Quality Medicine,.Hisun’s core operations in Taizhou city cover a very large area and are divided into three parts (the Yantou campus; Waisha Campus; and East Factory) which are separated by public roads. The Taizhou site employs approximately 4,000 people and focuses on fermentation-based anti-infectives, cardiovascular products (e.g. statins) along with synthetic anti-cancer products.   Hisun’s branded generic player ambitions Two years ago, Hisun’s ambitions to transform itself from an API maker to a branded generic company were announced through the launch of Hisun-Pfizer Pharmaceutical Co., a joint venture with Pfizer where Hisun has a controlling stake of 51 percent while Pfizer has the balance 49 percent.With a vision to become “a widely respected international pharmaceutical company,” Hisun exports more than “80 percent of its API products” to more than 30 nations and regions. Hisun will not disappear post the import banHowever, Hisun’s importance in the supply chain is demonstrated by the number of exemptions which the FDA had to make in order to ensure that there are no drug shortages created as an outcome of the import alert. Fourteen products have been excluded from the import alert. Bleomycin, Capreomycin, Daunorubicin Citrate Liposomal, Doxorubicin Hydrochloride, Mitomycin, Tazobactam, Granisetron, Cladribine, Cyclophosphamide finished form and API, Cytarabine, Floxuridine, Fludarabine, Ivermectin and Adenosine  will still be allowed entry into the United States from the Hisun plant. Our viewLast month we analyzed if “speedy action by European agencies suggest revival of API production in the West” and suggested that the era where companies were securing their supply of APIs by looking for low-cost players in Asia appears to be waning away.With a major Chinese player like Hisun now running into severe compliance problems and the number of alternatives available being quite limited, we foresee a significant shift in the pharmaceutical supply chain. 

    Impressions: 9873

    subscribeSubscribe
    ExcelExcel Download

    https://www.pharmacompass.com/radio-compass-blog/zhejiang-hisun-s-fda-import-alert-a-new-chapter-in-the-fight-against-data-integrity

    #Phispers by PHARMACOMPASS
    17 Sep 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search